93 related articles for article (PubMed ID: 31051328)
1. First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter.
Belohlavkova P; Steinerova K; Karas M; Skoumalova I; Rohon P; Indrak K; Voglova J; Vrbacky F; Cmunt E; Necasova T; Kristkova Z; Trneny M; Zak P; Papajik T; Faber E
Leuk Res; 2019 Jun; 81():67-74. PubMed ID: 31051328
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Eşkazan AE; Özmen D; Öztaş M; Bektaş F; Bayraktar EA; Sadri S; Keskin D; Özgür Yurttaş N; Elverdi T; Salihoğlu A; Ar MC; Öngören Ş; Başlar Z; Aydın Y; Soysal T
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):549-557. PubMed ID: 34052176
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
[TBL] [Abstract][Full Text] [Related]
5. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
6. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
[TBL] [Abstract][Full Text] [Related]
7. Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy.
Ćojbašić I; Mačukanović-Golubović L; Vučić M; Tijanić I
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):696-702. PubMed ID: 28712742
[TBL] [Abstract][Full Text] [Related]
8. Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study.
Alsobhi E; Abrar MB; Abdelaal M; Alsaeed A; Absi A; Alzahrani Z; El-Hemaidi I; Alshehri MA; Warsi A; Bayashoot S; Hashem H; Merdad A; Radi S; Shiekhi H; Al-Amri A
Leuk Lymphoma; 2015 Apr; 56(4):882-6. PubMed ID: 24956142
[TBL] [Abstract][Full Text] [Related]
9. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
[TBL] [Abstract][Full Text] [Related]
10. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
[TBL] [Abstract][Full Text] [Related]
11. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
[TBL] [Abstract][Full Text] [Related]
12. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.
Nicolini FE; Alcazer V; Cony-Makhoul P; Heiblig M; Morisset S; Fossard G; Bidet A; Schmitt A; Sobh M; Hayette S; Mahon FX; Dulucq S; Etienne G
Exp Hematol; 2018 Aug; 64():97-105.e4. PubMed ID: 29800673
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Cesini L; Carmosino I; Breccia M; De Benedittis D; Mohamed S; De Luca ML; Colafigli G; Molica M; Scalzulli E; Massaro F; Mariggiò E; Rizzo L; Loglisci MG; Scamuffa MC; Vozella F; Diverio D; Mancini M; Alimena G; Foà R; Latagliata R
Oncol Res Treat; 2019; 42(12):660-664. PubMed ID: 31593970
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
17. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
18. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Crugnola M; Castagnetti F; Breccia M; Ferrero D; Trawinska MM; Abruzzese E; Annunziata M; Stagno F; Tiribelli M; Binotto G; Bonifacio M; Fava C; Iurlo A; Bucelli C; Mansueto G; Gozzini A; Falzetti F; Montefusco E; Crisà E; Gugliotta G; Russo S; Cedrone M; RussoRossi A; Pregno P; Isidori A; Mauro E; Atelda R; Giglio G; Celesti F; Sorà F; Storti S; D'Addosio A; Galimberti S; Orlandi E; Calistri E; Bocchia M; Cavazzini F; Rege Cambrin G; Orofino N; Luciano L; Sgherza N; Rosti G; Latagliata R; Capodanno I
Ann Hematol; 2019 Oct; 98(10):2329-2338. PubMed ID: 31392461
[TBL] [Abstract][Full Text] [Related]
19. Long term outcome of chronic myeloid leukemia patients treated with imatinib: Report from a developing country.
Absar M; Akhtar T; Jameel A; Mahmood A; Ullah A; Aleem A; Qureshi K; Rehman N; Iqbal Z
Pak J Pharm Sci; 2020 Mar; 33(2(Supplementary)):861-870. PubMed ID: 32863263
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
